Aprogen Pharmaceuticals Inc (003060) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Aprogen Pharmaceuticals Inc (003060) has a cash flow conversion efficiency ratio of -0.024x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-7.66 Billion ≈ $-5.19 Million USD) by net assets (₩315.16 Billion ≈ $213.58 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Aprogen Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2010–2024)
This chart illustrates how Aprogen Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Aprogen Pharmaceuticals Inc for a breakdown of total debt and financial obligations.
Aprogen Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aprogen Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GHCL Limited
NSE:GHCL
|
0.089x |
|
Jilin Jinguan Electric Co Ltd Class A
SHE:300510
|
0.030x |
|
Titan International Inc
NYSE:TWI
|
0.025x |
|
C&C Group PLC
F:GCC
|
0.023x |
|
ForFarmers NV
AS:FFARM
|
0.158x |
|
Jereissati Participações S.A.
SA:IGTI3
|
0.029x |
|
Youngy Health Co Ltd
SHE:300247
|
-0.015x |
|
Lutian Machinery Co Ltd
SHG:605259
|
-0.005x |
Annual Cash Flow Conversion Efficiency for Aprogen Pharmaceuticals Inc (2010–2024)
The table below shows the annual cash flow conversion efficiency of Aprogen Pharmaceuticals Inc from 2010 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Aprogen Pharmaceuticals Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩378.69 Billion ≈ $256.63 Million |
₩-31.00 Billion ≈ $-21.01 Million |
-0.082x | +10.32% |
| 2023-12-31 | ₩368.69 Billion ≈ $249.86 Million |
₩-33.65 Billion ≈ $-22.80 Million |
-0.091x | -281.07% |
| 2022-12-31 | ₩510.41 Billion ≈ $345.90 Million |
₩25.73 Billion ≈ $17.44 Million |
0.050x | +583.45% |
| 2021-12-31 | ₩597.18 Billion ≈ $404.70 Million |
₩-6.23 Billion ≈ $-4.22 Million |
-0.010x | -177.13% |
| 2020-12-31 | ₩598.36 Billion ≈ $405.50 Million |
₩8.09 Billion ≈ $5.48 Million |
0.014x | +558.38% |
| 2019-12-31 | ₩347.64 Billion ≈ $235.59 Million |
₩713.73 Million ≈ $483.69K |
0.002x | -76.79% |
| 2018-12-31 | ₩150.51 Billion ≈ $102.00 Million |
₩1.33 Billion ≈ $902.26K |
0.009x | +107.71% |
| 2017-12-31 | ₩77.86 Billion ≈ $52.77 Million |
₩-8.93 Billion ≈ $-6.05 Million |
-0.115x | -2090.66% |
| 2016-12-31 | ₩78.12 Billion ≈ $52.94 Million |
₩449.98 Million ≈ $304.95K |
0.006x | -78.87% |
| 2015-12-31 | ₩67.75 Billion ≈ $45.91 Million |
₩1.85 Billion ≈ $1.25 Million |
0.027x | +124.48% |
| 2014-12-31 | ₩62.11 Billion ≈ $42.09 Million |
₩-6.92 Billion ≈ $-4.69 Million |
-0.111x | -270.03% |
| 2013-12-31 | ₩56.55 Billion ≈ $38.32 Million |
₩-1.70 Billion ≈ $-1.15 Million |
-0.030x | -619.64% |
| 2010-12-31 | ₩42.81 Billion ≈ $29.01 Million |
₩247.92 Million ≈ $168.01K |
0.006x | -- |
About Aprogen Pharmaceuticals Inc
Aprogen Biologics Inc. manufactures and sells pharmaceutical products primarily in South Korea. The company was founded in 1960 and is headquartered in Seoul, South Korea.